The complex network of interactions present in the tumor microenvironment has in recent years risen, as the new frontier of targeted cancer therapies for a number of malignant tumors, with the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway as the currently most widely utilized target. This evidence concerns the gene CD274 and neoplasm.